Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson

Namodenoson’s Favorable Safety Profile and Broad Patent Portfolio Positions it as a Promising Candidate in the Growing Obesity Treatment Market Ramat Gan, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company advancing a pipeline of proprietary small molecule drugs addressing oncological and inflammatory diseases, today announced the publication of a peer-reviewed study in the International Journal of Obesity demonstratin ...